Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2024-04-01 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window for insiders in compliance with SEBI regulations. It mentions the trading window closure period around the announcement of financial results but does not contain any financial data, results, or detailed report content. The document length is short (2100 characters) and serves as an announcement rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers compliance-related announcements and miscellaneous regulatory communications that do not fit other categories.
2024-04-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notification letter addressed to stock exchanges (BSE and NSE) regarding the issuance of a Certificate of Good Manufacturing Practices (EUGMP) by the Government of Upper Franconia for the company's manufacturing facility. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to material event disclosures. The document does not contain financial data, management discussion, or detailed report content. It is an announcement of a regulatory or compliance event rather than a financial report or detailed filing. The length is only 2136 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-22 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notification addressed to stock exchanges regarding the issuance of a Good Manufacturing Practices (GMP) certificate by the Brazilian Health Regulatory Agency (ANVISA) for the company's facility. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to material event disclosures. The document does not contain financial data, detailed reports, or management discussion. It is an announcement of a regulatory compliance event rather than a financial report or detailed filing. The document length is only 1713 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about the completion of an inspection by the Ministry of Health Pharmacy and Poisons Board, Republic of Kenya, at the company's manufacturing unit. It states the inspection was successful and the company received a Good Manufacturing Practices certificate. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The document is short (2057 characters) and serves as an announcement of an event rather than a detailed report or financial filing. It does not contain financial data, management discussion, or audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-02-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 and 9 months FY24 earnings conference call for Concord Biotech Limited held on February 09, 2024. It includes management commentary on financial performance, operational highlights, strategic outlook, and a Q&A session format typical of earnings call transcripts. The document references the unaudited financial results for the quarter and nine months ended December 31, 2023, and mentions the availability of the audio recording and transcript on the company's website. The presence of management speakers, moderator, forward-looking statements disclaimer, and detailed discussion of quarterly and nine-month financial results confirms this is a Call Transcript (CT).
2024-02-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Concord Biotech Limited to stock exchanges (NSE and BSE) informing about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, specifically Regulation 30(6), which pertains to disclosure of events or information. The content is about upcoming investor meetings and explicitly states that no unpublished price sensitive information will be discussed. The document is short (2475 characters) and serves as an announcement or intimation rather than a detailed report or transcript. It does not contain financial data, management discussion, or detailed presentations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2024-02-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.